Polatuzumab vedotin | Interleukin Related interleukin-related.com

Product Name :
Polatuzumab vedotin

Search keywords :
Val-Cit

drugId :
null

Target Vo:
Tubulin

Target Vo Short Name :
Tubulin

Moa_Name:
Tubulin polymerisation inhibitors

First Approval Country :
United States

First Approval Date Filter:
2019

Origin Company_Name :
Seagen Inc

Active Company_Name :
Bsp Pharmaceuticals Spa

Active Indication_Name:
Lymphoma, Large B-Cell, Diffuse

In Active Indication_Name:
Leukemia, Lymphocytic, Chronic, B-Cell

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Lanadelumab Description
Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) Autophagy
BRD4 Antibody: BRD4 Antibody is an antibody about 152 kDa, targeting to BRD4.

Author: Interleukin Related

Related Posts